Q-omics provides the consensus-scored USP19 profile across patient tissues and cancer cell-line models. USP19 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, USP19 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, USP19 RNA expression shows 20,009 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where USP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP19 survival associations across molecular data types. USP19 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP19 RNA expression–survival associations across cancer types. High USP19 expression shows unfavorable associations in ACC, but favorable associations in UVM, BRCA, KIRC, HNSC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for USP19 RNA expression.
This table summarizes USP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for USP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP19 shows lower tumor expression in KIRC, THCA, BRCA and KICH and higher tumor expression in LIHC and CHOL. The KIRC box plot shows higher USP19 RNA expression in normal versus tumor tissue (log2 FC = −0.817, t-test p < 0.001).
This table shows molecular features associated with USP19 in patient tissues and cancer cell lines. In patient samples, USP19 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, USP19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
